J&J returning as a growth stock
Investor's Digest of Canada •2014-09-19 •
Technology and health care analyst Steven Zicherman of Vancouver-based Odlum Brown reiterates his “buy” recommendation and 12-month target price of $117 for health-care giant Johnson & Johnson (JNJ—NYSE).
The company, which Read More